Cancer neuroendocrine tumours

Pulmonary cancer Neuroendocrine tumour (i.e. carcinoids) Hepatocellular and cholangiocellular cancer tissue tumour Renal cell cancer Osseous cancer... 

Kolby L, Bernhardt P, Levin-Jakobsen AM, Johanson V, Wangberg B, Ahlman H, Forssell-Aronsson E, Nilsson O (2003) Uptake of meta-iodobenzylguanidine in neuroendocrine tumours is mediated by vesicular monoamine transporters. Br J Cancer 89 1383-1388. 

To date, resection of liver metastases of colorectal or neuroendocrine tumours is the only treatment option which may result in definitive removal of the cancerous disease. Resection is indicated in those cases in which the primary tumour can be removed completely and when no further metastases are detectable. Repeated resection is also possible. Extrahepatic metastases or involvement of neighbouring organs are generally no longer regarded as contraindications. (3ll, 316, 317)... 

Morbidity should not exceed 30%. Lethality is between 0-3%. The 5-year survival rate following RO resection in metastatic colorectal carcinoma is 20-40%, in neuroendocrine tumours 90-100%, in malignant melanoma 15-25%, and in breast cancer 10-30%. Prognosis is poor in metastasizing renal cell carcinoma and in gastric or pancreatic carcinoma. Both R1 and R2 resection worsen the prognosis to the same extent. 

Systemic chemotherapy is usually not indicated in non-colorectal liver metastases due to lack of response. The systemic administration of cytostatics (also in combination) possesses the status of palliative therapy. However, in metastatic neuroendocrine tumours, a combination of octreotide -i- IFN had a positive effect on the survival time. Systemic chemotherapy produced remission rates of up to 60%. (320) In metastatic breast cancer, systemic chemotherapy is indicated, usually in combination with hormonal and immune therapy. (316, 342) In metastatic gastric carcinoma, palliative chemotherapy can achieve a remission rate of up to 40%, with a slight extension of survival time. 

Bernini GP, Moretti A, Ferdeghini M, et al. A new human chromogranin A immunoradiometric assay for the diagnosis of neuroendocrine tumours. Br J Cancer 2001 84 636-42. 

Barakat MT, Meeran K, Bloom SR. Neuroendocrine tumours. Endocrine-Related Cancer 2004 11 1-18. 

FROIDEVAUSX, S., et al.. Neuroendocrine tumour targeting Study of novel gallium-labelled somatostatin radiopeptides in a rat pancreatic tumour model, Int. J. Cancer 98 (2002) 930-937. 

Christenson ES, James T, Agrawal V, Park BH (2015) Use of biomarkers for the assessment of chemotherapy-induced cardiac toxicity. Clin Biochem 48 223-235 Conway A, McCarthy AL, Lawrence P, Clark RA (2015) The prevention, detection and management of cancer treatment-induced cardiotoxicity a meta-review. BMC Cancer 15 366 Cummins M, Pavlakis N (2013) The use of targeted therapies in pancreatic neuroendocrine tumours patient assessment, treatment administration, and management of adverse events. Ther Adv Med Oncol 5 286-300... 

Castellan MR, Chiti A, Seregni E, et al. (2000) Role of 131Imetaiodobenzylguanidine (MIBG) in the treatment of neuroendocrine tumours. Experience of the National Cancer Institute of Milan. Q J Nucl Med 44 77-87... 

The liver is the most common site of metastatic disease. Hepatic metastases most commonly occur from colorectal cancer and, less frequently, from neuroendocrine tumours, gastrointestinal sarcoma, ocular melanoma, and others. Complete evaluation of the extent of metastatic disease, both within and outside the liver, is important before considering treatment options. 

Abrahamsson PA. Neuroendocrine cells in tumour growth of the prostate. Endocr Relat Cancer. 1999 6 503. 

---